It was February 22nd when the virologist Giorgio Palù, confirmed as president of the new Aifa just a couple of...
Read more“It takes years for a diagnosis of severe asthma and just as many for treatment. The new therapies are also...
Read more“Today is an important day for us, precisely in the respiratory sector, one of the historic areas of AstraZeneca”, because...
Read moreWith a press conference held today in Milan, the global biopharmaceutical company AstraZeneca announced that the monoclonal antibody tezepelumab, the...
Read more“Tezepelumab is a biological drug that acts upstream of the inflammatory cascade, impacting alarmin, one of the three cytokines that...
Read more"Tezepelumab is the first anti-Tslp biologic approved in our country. This confirms AstraZeneca's commitment in the respiratory field and in...
Read more“The use of biologics has radically changed the treatment of patients with severe asthma. Thanks to them it is possible...
Read more"The advantage of tezepelumab is that it acts on an upstream target in the pathophysiology of asthma" and is therefore...
Read more"The advantage of tezepelumab is that it acts on an upstream target in the pathophysiology of asthma" and is therefore...
Read moreIn collaboration with: Dr. De Masi Modern psychology deals with a wide range of disorders, and among these, anxiety, hypochondria...
Read more